Silence Therapeutics Plc (SLN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Silence Therapeutics Plc has reported a narrowed loss after taxation to £1,876 thousand for the first quarter of 2024 compared to £10,204 thousand in the same period last year, reflecting improved revenue and reduced operating expenses. The company’s financial position shows a significant increase in net assets, with cash and cash equivalents rising to £113,056 thousand from £54,031 thousand at the end of December 2023.
For further insights into SLN stock, check out TipRanks’ Stock Analysis page.